46-3405526 · Durham, NC
THE RARE CANCER RESEARCH FOUNDATION IS DEDICATED TO CURING RARE CANCERS THROUGH STRATEGIC INVESTMENTS AND COLLABORATIONS THAT CATALYZE EFFECTIVE RESEARCH AND ACCELERATE DEPLOYMENT OF PROMISING THERAPIES.
Total revenue
$3.5M
FY2023
Total expenses
$2.2M
FY2023
Net assets
$2.1M
FY2023
Operating margin
38.1%
NPLens analysis
FY18–FY2023 · from annual filings
Financial health
B+
Derived analysis — not an official IRS designation.
Computed from FY2023 · derived analysis
FY2023 · program vs. administration vs. fundraising (Form 990, Part IX)
FY2023 · where revenue comes from (as reported)
Highest-paid officers, directors & key employees · FY2023.
MARSHALL THOMPSON
PRESIDENT
$194,426
AMBER SMITH
BIOBANK MANA
$141,892
BARBARA VAN HARE
PRES. OF PAT
$126,664
CHRIS HEERY
DIRECTOR
$0
MARK LAABS
FOUNDER & CH
$0
Each figure on this page traces to one of these source returns.
Health scores, efficiency ratios, peer percentiles, and outlier flags are derived analysis by NPLens — not official IRS designations. Figures are as reported on the organization's Form 990 filings. How these are computed →